Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics
Introduction Brensocatib is an investigational, oral, reversible inhibitor of dipeptidyl peptidase-1 shown to prolong time to first exacerbation in adults with bronchiectasis. Outlined here are the clinical trial design, and baseline characteristics and treatment patterns of adult patients enrolled...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2024-07-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/10/4/00151-2024.full |